Seeking Alpha

Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda...

Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros.
Comments (1)
  • Vitaros will be launched this year. Apri have signed a big contract with Takeda and have contracts in different countries in Europe.
    After Viagra who was not so good for the liver, heart and eyes we are looking for the launch of Vitaros by Health Canada and the launch is for this year. It will be a blockbuster, no doubt about it . Every people will love and love is a reason for life. Enjoy Apri now , it is time to buy.
    14 Sep 2012, 04:00 AM Reply Like
DJIA (DIA) S&P 500 (SPY)